Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L A McDermott

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Antimicrobial Agents and Chemotherapy|May 16, 2019
U.S.-Based National Surveillance for Fidaxomicin Susceptibility of Clostridioides difficile-Associated Diarrheal Isolates from 2013 to 2016C M Thorpe, L A McDermott, M K Tran, et al.
Antimicrobial Agents and Chemotherapy|August 5, 2015
U.S.-Based National Sentinel Surveillance Study for the Epidemiology of Clostridium difficile-Associated Diarrheal Isolates and Their Susceptibility to FidaxomicinD R Snydman, L A McDermott, N V Jacobus, et al.
Antimicrobial Agents and Chemotherapy|October 3, 1999
Multicenter study of in vitro susceptibility of the Bacteroides fragilis group, 1995 to 1996, with comparison of resistance trends from 1990 to 1996D R Snydman, N V Jacobus, L A McDermott, et al.
Journal of Applied Microbiology|March 4, 2017
Selective method for identification and quantification of Bifidobacterium animalis subspecies lactis BB-12 (BB-12) from the gastrointestinal tract of healthy volunteers ingesting a combination probiotic of BB-12 and Lactobacillus rhamnosus GGD D Poutsiaka, I J Mahoney, L A McDermott, et al.
Anaerobe|June 14, 2011
Update on resistance of Bacteroides fragilis group and related species with special attention to carbapenems 2006-2009D R Snydman, N V Jacobus, L A McDermott, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 13, 2002
National survey on the susceptibility of Bacteroides Fragilis Group: report and analysis of trends for 1997-2000D R Snydman, N V Jacobus, L A McDermott, et al.
Antimicrobial Agents and Chemotherapy|February 7, 2007
National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004D R Snydman, N V Jacobus, L A McDermott, et al.
Antimicrobial Agents and Chemotherapy|September 20, 2023
A US-based national surveillance study for the susceptibility and epidemiology of <i>Clostridioides difficile</i> isolates with special reference to ridinilazole: 2020-2021D R Snydman, L A McDermott, C M Thorpe, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Antimicrobial Agents and Chemotherapy|May 16, 2019
U.S.-Based National Surveillance for Fidaxomicin Susceptibility of Clostridioides difficile-Associated Diarrheal Isolates from 2013 to 2016C M Thorpe, L A McDermott, M K Tran, et al.
Antimicrobial Agents and Chemotherapy|August 5, 2015
U.S.-Based National Sentinel Surveillance Study for the Epidemiology of Clostridium difficile-Associated Diarrheal Isolates and Their Susceptibility to FidaxomicinD R Snydman, L A McDermott, N V Jacobus, et al.
Antimicrobial Agents and Chemotherapy|October 3, 1999
Multicenter study of in vitro susceptibility of the Bacteroides fragilis group, 1995 to 1996, with comparison of resistance trends from 1990 to 1996D R Snydman, N V Jacobus, L A McDermott, et al.
Journal of Applied Microbiology|March 4, 2017
Selective method for identification and quantification of Bifidobacterium animalis subspecies lactis BB-12 (BB-12) from the gastrointestinal tract of healthy volunteers ingesting a combination probiotic of BB-12 and Lactobacillus rhamnosus GGD D Poutsiaka, I J Mahoney, L A McDermott, et al.
Anaerobe|June 14, 2011
Update on resistance of Bacteroides fragilis group and related species with special attention to carbapenems 2006-2009D R Snydman, N V Jacobus, L A McDermott, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 13, 2002
National survey on the susceptibility of Bacteroides Fragilis Group: report and analysis of trends for 1997-2000D R Snydman, N V Jacobus, L A McDermott, et al.
Antimicrobial Agents and Chemotherapy|February 7, 2007
National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004D R Snydman, N V Jacobus, L A McDermott, et al.
Antimicrobial Agents and Chemotherapy|September 20, 2023
A US-based national surveillance study for the susceptibility and epidemiology of <i>Clostridioides difficile</i> isolates with special reference to ridinilazole: 2020-2021D R Snydman, L A McDermott, C M Thorpe, et al.
Pageof 2